V iii iii iv iii iv() iii ii ii iii iii ii iv() Nov-10 Jun-11 iii ii ii ii ii ii ii Completed Completed Recruiting Completed Stohl w, 2013 No study results posted Recruiting No study results posted Jan-05 Time to initial relapse Percentage of sufferers with ACR20 response at week 24 Transform in modified Rodnan Skin Score at 48 weeks Terminated At ClinicalTrials.gov Ongoing No study benefits posted Completed van vollenhoven RF, 2012; Stohl w, 2012 Completed Navarra Sv, 2001 Recruiting No study final results posted Recruiting No study benefits posted Completed Furie R, 2008; Struemper H, 2013 Recruiting No study benefits posted Completed wallace DJ, 2009; Furie, RA, 2009 Recruiting No study results posted Recruiting No study results posted Ongoing No study results posted Recruiting No study results posted Ongoing No study final results posted Completed No study benefits posted Recruiting No study final results posted Recruiting No study outcomes posted Ongoing Ginzler eM, 2014 Recruiting No study results posted Recruiting No study results posted Recruiting No study outcomes posted Completed No study results posted Terminated No study results posted Oct-11 Recruiting No study outcomes posted No study outcomes posted Dec-11 No study benefits posted Aug-12 Response rate (safety/efficacy study) Proof of notion of efficacy of belimumab in subjects with SSBLiSS-NCT00424476 NCT01597492 NCT01532310 NCTincidence of adverse events of particular interest Percent modify at SeLeNA-SLeDAi at week 24 (security and efficacy) incidence of all-cause mortality (52 weeks) Number of participants having a renal response at week 104 SRi response rate subcutaneous administration Response price at 52 weeks black race Long-term security of belimumab in SLe Responder rate at week 52 Belimumab remedy holiday and treatment restart study in lupus individuals SRi pediatric lupus Long-term αvβ3 Antagonist custom synthesis safety of LymphoStat-BTM in SLe SRi response price at week 52 in SLe pts located in Northeast Asia Long-term safety of belimumab in subjects with SLe in Northeast Asia Suitability on the autoinjector for self-administration of belimumab by subjects with SLe Efficacy and safety within a subgroup of SLE patients: pooled data from the BLISS-52 and BLISS-submit your manuscript | dovepressNCT01729455 Major endpoint NCT00071487 not met NCT01705977 NCT01639339 NCT01484496 NCT01632241 NCT00712933 Pooled NCT01914770 NCT02119156 NCT01649765 α4β7 Antagonist Source NCT00583362 NCT01345253 NCT01597622 NCT02124798 NCT01858792 Vasculitis BRevAS NCT01663623 RA Mild efficacy NCT00071812 Scleroderma Diffuse reduce SScl NCT01670565 Transplantation NCT01025193 NCT01536379 Sj ren’s syndrome BeLiSS NCT01160666 NCTDesensitization before kidney transplant Prevention of allograft rejection in adult subjects after renal transplantation (pilot, single center)Targeting BAFF for the therapy of AAvDovepressAbbreviations: Ae, adverse occasion; BAFF, B-cell-activating aspect in the TNF loved ones; BRevAS, Belimumab in Remission of vasculitis; igG, immunoglobulin G; RA, rheumatoid arthritis; SLe, systemic lupus erythematosus; SRi, SLe responder index; SS, Sj ren’s syndrome.Lenert and LenertDovepressTable four Clinical trials with tabalumab and blisibimodClinical trial SLE NCT02041091 NCT01196091 NCT01205438 NCT01488708 NCT01676701 NCT00689728 NCT00785928 NCT01253226 NCT01576549 NCT00308282 NCT01198002 NCT01202760 NCT01202773 NCT00837811 NCT01215942 Phase iii iii iii iii iii ii ii i ii ii iii iii iii ii iii Status Recruiting Active, not recruiting Completed By invitation only Completed Full.
